San Raffaele Diabetes Research Institute (HSR-DRI), 20132, Milano, Italy.
Adv Exp Med Biol. 2010;654:725-47. doi: 10.1007/978-90-481-3271-3_32.
We acknowledge that successful long-term islet survival in the liver and immune tolerance to intrahepatic islet antigens are highly dependent upon the initial inflammatory and priming events that occur at this site. Thromboembolic and necroinflammatory events occurring in the liver early after portal vein islet transplantation are thought to reduce the total islet mass by up to 75%. The magnitude of such loss represents a major factor necessitating the extremely large number of islets needed to achieve normoglycemia. A better understanding and control of these events - including their likely support to effector immune responses - are required if we are to develop ways to prevent them, improve intrahepatic islet engraftment, and achieve long-term tolerance.
我们认识到，肝内胰岛的长期存活和对其抗原的免疫耐受高度依赖于该部位初始的炎症和启动事件。门静脉胰岛移植后早期发生的血栓栓塞和坏死性炎症事件被认为会使胰岛总量减少多达 75%。如此大的损失量是导致需要大量胰岛才能实现血糖正常的主要因素之一。如果我们要开发预防这些事件的方法、改善肝内胰岛移植的效果并实现长期耐受，就需要更好地理解和控制这些事件，包括它们可能对效应免疫反应的支持。
